Editas Medicine (EDIT) PT Lowered to $9 at Barclays
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $2.58 -6.18%
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Barclays analyst Gena Wang lowered the price target on Editas Medicine (NASDAQ: EDIT) to $9.00 (from $11.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Guggenheim Upgrades Editas Medicine (EDIT) to Buy
- Wipro Ltd. (WPRO:IN) (WIT) PT Lowered to INR140 at Citi
- Slate Grocery REIT (SGR-U:CN) (SRRTF) PT Lowered to $8.75 at Scotiabank
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
